Palladium-catalyzed decarboxylative ortho-aroylation of N-acetyl-1,2,3,4-tetrahydroquinolines with α-oxoarylacetic acids
作者:Lu Han、Yahui Wang、He Song、Huatao Han、Lulu Wang、Wenyi Chu、Zhizhong Sun
DOI:10.1039/c6ra00163g
日期:——
A mild, practical and efficient palladium-catalyzeddecarboxylative ortho-aroylation of N-acetyl-1,2,3,4-tetrahydroquinolines with α-oxoarylacetic acids via C–H bond activation is described. This protocol provides efficient access to a series of C8-aroyl terahydroquinolines.
[EN] TETRAHYDROISOQUINOLINE COMPOUNDS AND THEIR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS<br/>[FR] COMPOSÉS TÉTRAHYDROISOQUINOLÉINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PYRUVATE DÉSHYDROGÉNASE KINASE
申请人:VERNALIS R & D LTD
公开号:WO2015040424A1
公开(公告)日:2015-03-26
A compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: R1 is H, Cl, F, CH3 or CF3; R2 is H, C1-C6 alkyl or optionally substituted heteroaryl or optionally substituted aryl; and R3 is (Alk)n-Rn-(Alk)n-Rn-(Alk)n-X. The compounds are useful as tetrahydroisoquinoline (THQ) compounds, which are suitable for use as PDK inhibitors, for example for inhibition of cancer cell proliferation.
coupling/intramolecular cyclization is reported. The one-pot synthesis system provides mild, efficient, and atom economical access to the synthesis of 4-aryl-2-quinolinone derivatives. It is notable that the necessary oxidant in the traditional decarboxylation coupling is replaced by the visible-light irradiation in this paper. In addition, the HBV inhibitor is synthesized by the one-pot synthesis system
[EN] DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF<br/>[FR] DÉRIVÉS DE DÉCAHYDROQUINOXALINE ET LEURS ANALOGUES
申请人:OTSUKA PHARMA CO LTD
公开号:WO2013137479A1
公开(公告)日:2013-09-19
A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents -O- or -CH2-; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).
[EN] HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE.<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT OU LA PRÉVENTION DE TROUBLES PROVOQUÉS PAR UNE NEUROTRANSMISSION RÉDUITE DE LA SÉROTONINE, DE LA NORÉPINEPHRINE OU DE LA DOPAMINE
申请人:OTSUKA PHARMA CO LTD
公开号:WO2012036253A1
公开(公告)日:2012-03-22
A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents -O- or -CH2-; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).